TrialAntimicrobial agents and chemotherapy2012

Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C.

Claudio Pasquinelli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.